leading with vision - Diabetes Research Institute

Transcription

leading with vision
[2009 annual report]
[Over the last two years, we have undergone an extensive re-engineering effort
to transform the DRI into a cure-focused machine. The goal: to be more efficient
than any other research institution in moving promising discoveries from the
lab to clinical application.]
In this new era of research,
the DRI is Leading with Vision
by applying fresh thinking,
revolutionary ideas, sweeping
efficiencies and a steadfast
commitment to aggressively
pursuing a cure for diabetes.
1 [2009 annual report]
About the Diabetes
Research Institute
2
Mission and Goals
4
Message from the
Scientific Director
6
Research Review
8
Faculty and Staff Listing
26
About the Diabetes Research
Institute Foundation
30
Message from the Chairman
and President
32
Financial Statement
34
To our Donors
36
The Heritage Society
42
National Board of Directors
43
Honorary and
Regional Boards
44
DRI Foundation Staff
45
about
[the DRI]
The Diabetes Research Institute is a recognized world leader in
cure-focused research. Since its inception in the early 1970s, the
DRI has made significant contributions to the field of diabetes
research, pioneering many of the techniques used in islet
transplantation. From innovations in islet isolation and transplant
procedures to advances in cell biology and immunology, the DRI
is now bridging cell-based therapies with emerging technologies
to restore insulin production.
[diabetes research institute foundation] 2
The most comprehensive diabetes research center
of its kind, the DRI is credited with changing the
international research paradigm, ensuring that
promising findings in the lab can be translated to
patients in the fastest, safest and most efficient
way possible. Through this translational process,
the DRI bridges research programs in the rapidly
evolving fields of pancreatic stem cell development,
tissue engineering, transplant immunology,
cell transdifferentiation, molecular biology and
regenerative medicine, among others, to approach
the cure with a true multidisciplinary strategy.
Pioneering New Therapies to Restore
Insulin Production
The Institute is an innovator in several research
areas; however its principle focus is the biological
replacement of insulin function to restore blood
sugar control.
Known for its groundbreaking work in islet
transplantation resulting in normalized blood
sugar levels in study patients, the DRI is now
improving transplant processes and addressing
the remaining challenges that limit the procedure’s
widespread application.
Beyond islet transplantation, the DRI is opening new
doors to discovery by developing novel approaches to
restore natural insulin function. Scientists from a broad
range of disciplines are applying their expertise by:
•
•
•
•
•
constructing tissue-engineered barriers
and bio-devices
generating new, small molecules to eliminate
the need for immune suppressing drugs
developing sophisticated techniques to assess
islet viability and predict long-term function
transforming select cells of the body into
insulin-producing cells
exploring methods to regenerate islets
within the native pancreas.
The Hub of a Global Research Alliance
The DRI has a long history of scientific collaboration,
but the most focused and far-reaching initiative to
date is the Diabetes Research Institute Federation.
Comprised of a dozen medical centers on almost
every continent, the DRI Federation is an international
network of leading scientists who are sharing
knowledge, applying their respective expertise to
key research areas, and concentrating solely on
curing the disease.
The Institute’s open-door philosophy provides
opportunities for scientists and biomedical companies
around the world to utilize the DRI’s state-of-the-art
facilities and expertise to quickly and efficiently
evaluate promising new research strategies. Much of
this work begins in the DRI’s Fast Track Center for
3
Testing, where investigators can access all three of
the fundamental phases of research – basic (in the lab),
pre-clinical (study models), and clinical (patient studies)
– under one roof. This translational approach and
structure enables researchers to take potential new
therapies begun in the lab and further develop these
techniques to benefit those with diabetes.
The DRI applies this same collaborative approach as a
training center, hosting international conferences and
conducting hands-on workshops for visiting scientists.
The Institute also facilitates the distribution of its
specialized cell processing equipment and other devices
to researchers throughout the world. This includes the
system that separates healthy insulin-producing islets
from a donor pancreas, which was invented by the DRI’s
scientific director, Dr. Camillo Ricordi.
Consistent Competitive Funding
DRI scientists have been awarded competitive federal
and state grants for more than 30 consecutive years.
The resulting research findings have been published
extensively in peer-reviewed journals and the
DRI’s many innovations are used in diabetes centers
worldwide. As leaders in their fields, the Institute’s
faculty serves on numerous national and international
committees, scientific review panels and medical
associations to provide and interpret scientific data
and assist in strategic planning.
While competitive research grants are the mainstay of
world-class research institutes, the Diabetes Research
Institute Foundation provides the DRI with the critical
seed funding necessary for developing and pursuing
new research initiatives. Supported by private
philanthropy, the DRI Foundation also fills the gaps
in many stages of the research process that are not
covered by grants and other funding sources.
A Community Resource
A designated Center of Excellence at the University
of Miami Miller School of Medicine, the DRI provides
informative and practical Continuing Medical Education
programs for physicians, health care professionals
and industry representatives. For patients and their
families, the DRI’s Kosow Diabetes Treatment Center
offers an array of diabetes management and education
activities, as well as participation in clinical research
studies, ensuring the highest standards of health
care delivery.
The Best Hope for a Cure
With an unwavering commitment to cure those now
living with diabetes, along with its unique spirit of
collaboration and fast track approach to research,
the DRI is leading the international effort to cure
this disease. For the millions of families affected by
diabetes who are looking to the world of science
for answers, the DRI is the best hope for a cure.
5
mission
[and goals]
The Mission of the Diabetes Research Institute:
To develop and rapidly apply the most promising
research to treat and cure those now living
with diabetes.
Goals
• To foster a dynamic multidisciplinary research team comprised of basic and clinical
scientists that conduct innovative diabetes research.
• To facilitate the translation of new research findings into novel therapies for patients
with diabetes as quickly as possible.
• To improve clinical care and enhance the quality of life for all patients with diabetes
through professional training and education programs.
• To expand collaborative alliances with other leading centers of research, thus creating
a global intellectual environment, which streamlines research efforts worldwide and
furthers our mission to cure diabetes.
• To establish corporate, philanthropic and academic partnerships to share in the costs
of research and development, thus accelerating the testing of new approaches and
developments to cure diabetes.
7
5
from the
[scientific director]
Curing a disease is no small task.
Historically, the conquest and near eradication of major scourges
like smallpox and polio have required dedicated resources, creative
approaches and scientific insight that was uncommon for the
day. At the Diabetes Research Institute (DRI), we bring that same
disciplined pursuit of a cure to type 1 diabetes. This dedicated
effort, on the part of our entire research team, has enabled us to
make great strides toward this goal.
In a world of increasing economic challenges,
however, we must find ways to work smarter
while maintaining our unrelenting focus on a cure.
We must ensure that our resources are utilized
efficiently, that our creativity is constantly inspired,
and that our vision is keenly focused.
As the economy began its downward spiral in 2008,
the DRI made responsible adjustments to its research
plan to ensure that the most important work could
continue at full speed and leave no stone unturned
in pursuit of a cure. A number of consolidating steps
were taken to meet that mandate, and over the
last two years, we have undergone an extensive reengineering effort to transform the DRI into an even
more resourceful research enterprise. In that line of
thought, we have established four primary areas of
research, and prioritized the projects within them:
1
Cellular and Molecular Biology of the
Endocrine Pancreas
2 Sources of Insulin Producing Cells
and Regeneration
3 Nanotechnologies, Encapsulation/Biomaterials
and Devices
4 Immunomodulation and Tolerance.
Some projects were staggered, others moved to
collaborating laboratories that were less affected
by the slowing US economy. Our goal: to be more
efficient than any other research institution in
moving promising discoveries from the lab to
clinical application.
We’ve re-organized our research program into a
tight group of priority areas aimed at asking and
answering the most urgent scientific questions:
• Can we reprogram some cell types to become
insulin producing cell types - and can we do so
in large enough numbers to be clinically useful?
• How does the immune system attack that
precipitates diabetes actually occur, and can that
knowledge be tapped to reverse the process?
• Can we slow progression of new onset
diabetes by following critical biomarkers,
and can this knowledge help us eliminate
the disease altogether?
• How consistently can we push our own stem
cells down the path to creation of new
insulin-producing cells for our own use?
• What are the most efficient and reproducible
alternative sources for islets—will it be
from cord blood, mesenchymal stem cells,
amniotic fluid, or other potential sources
newly arrived on the research horizon?
• What is the optimal implantation site for
replacement cells, and what type of hybrid
device or nanoscale semipermeable barrier
will work best to protect them?
• Once new insulin producing cells are
transplanted, how can recurrence of
autoimmune attack be prevented?
• Can nanoparticles be used to produce
tolerance, and thus facilitate the survival
of replacement cells in patients?
This annual report highlights the paths being
explored at the Institute’s many interdisciplinary
labs and the most recent achievements we’ve made
together with our global network of Federation
scientists, who have been brought in to work on
the challenge with us.
Our one-of-a-kind international network of scientists
forms a living, breathing powerhouse of knowledge
that is intensely focused on making type 1 diabetes
a disease of the past.
Join us on the path of groundbreaking
discovery and let’s make diabetes history.
Camillo Ricordi, M.D.
Stacy Joy Goodman Professor of Surgery
Distinguished Professor of Medicine
Professor of Biomedical Engineering,
Microbiology & Immunology
Director, Diabetes Research Institute
and Cell Transplant Center
University of Miami
9
research
[review]
Since our inception, the Diabetes Research Institute has
been at the forefront of cure-focused research, pioneering
many of the approaches to restore natural insulin production
in those living with diabetes. Today, building upon almost four
decades of expertise, we are defining a new research strategy
for the 21st Century that is not typically found in academic
medicine. Over the last two years, we have undergone an
extensive re-engineering effort to transform the DRI into a
cure-focused machine. The goal: to be more efficient than any
other research institution in moving promising discoveries
from the lab to clinical application.
[
The Diabetes Research Institute is committed to moving research from the lab to the patient in the fastest,
safest way possible. At our Dr. Denise R. and Thomas D. Stern Fast Track Center for Testing, researchers evaluate
promising new technologies and potential therapies in a state-of-the-art environment where we have the ability
to advance research exponentially faster than what might be found in a traditional research environment.
Read more about it at DiabetesResearch.org
[diabetes research institute foundation]
8
We’ve unified the research process in what can best be called a “sequential, integrated” approach to
biomedical research. This approach ensures that every improvement made in a basic lab experiment
impacts the next level of research as the study moves forward to pre-clinical studies, and finally to clinical
trials. This approach has been optimized at the DRI, where unlike other diabetes research centers, all levels
of translational research are found under one roof so as to maximize collaborations and cross-fertilization
of ideas – from basic to clinical as well as across disciplines.
We have organized our research operation into four primary areas, each structured to fast-track research
concepts and eliminate wasted time. Information is regularly exchanged among our diverse faculty, whom
have expertise in a broad spectrum of disciplines from immunology and stem cell research to molecular
biology, engineering and more. We complement our internal expertise by collaborating with other leading
researchers throughout the world to reach our goal a cure as fast as humanly possible.
In this new era of research, the DRI is Leading with Vision—by applying fresh thinking, revolutionary ideas,
sweeping efficiencies and a steadfast commitment to aggressively pursuing a cure for diabetes now.
One small step forward in any of these
primary research areas can have a huge
impact on work being done by others
within the DRI's interconnected team.
Through this synergy, we’re able to pursue
a cure for diabetes from many angles.
Cellular and Molecular Biology of the
Endocrine Pancreas
Understanding cellular function, and dysfunction,
is key to finding a cure for diabetes. Our cellular and
molecular biology efforts encompass not only the
study of cells that produce insulin, but multiple
cell types that impact metabolism, transplantation
and regeneration. Their similarities and differences,
cellular architecture, response to cellular signals, and
a host of other molecular characteristics all play a role
in furthering the understanding of diabetes and the
development of new therapies to restore normal
metabolic function.
Sources of Insulin Producing
Cells and Regeneration
We are focusing on a number of strategies to
optimize cellular therapies for the treatment of
diabetes, including finding alternative cell sources
for use in transplantation to bridge the supply gap;
transdifferentiating cells (reprogramming one cell
type to grow into another); and even working in
the area of cell regeneration, which may ultimately
replace transplantation altogether.
Nanotechnologies, Encapsulation,
Biomaterials, Devices and Local
Drug Delivery
Investigators are using many newly available
technologies to enhance traditional cell-based
science and, as a result, are creating unparalleled
opportunities to treat and cure diseases. Here at
the DRI, researchers from such diverse disciplines
as engineering, immunology, biomaterials and
computer technology are working together as
never before, generating cutting-edge ideas to
solve the problems of diabetes.
Immunomodulation and Tolerance
To speed the process of developing and testing
promising immune system therapies, we have
assembled a specialized research team to focus
on designing next-generation drugs. Using highlyefficient computer modeling and advanced drug
design methods, we are working to develop small
molecules that can be specifically used to overcome
the unique immune system challenges posed in
type 1 diabetes.
11
9
A clear view of a functioning islet (bright gray) transplanted into the
anterior chamber of a mouse eye. Researchers are able to observe the
development of blood vessels (red) and can monitor immune responses.
In this study, T-lymphocytes (labeled green) travel through blood vessels
infiltrating the islet - causing the destruction of the insulin-producing
cells. This novel “living window” provides vital information on specific
immune system mechanisms and targets and will greatly impact
strategies to protect islets.
[
Visit our web site to hear a podcast on the
Living Window from Per-Olof Berggren, Ph.D.
DiabetesResearch.org
CELLULAR AND MOLECULAR BIOLOGY
OF THE ENDOCRINE PANCREAS
Our Molecular Biology and Immunogenetics teams study the most basic, essential aspect
of diabetes research: the science of cells. By understanding the molecular mechanics of cells,
we can begin to answer the fundamental questions about the function, growth and survival
of insulin-producing cells. This past year, we pursued a number of projects focused on the
study of cellular architecture, response to cellular signals, and a host of other molecular
characteristics which all play a role in furthering the understanding of diabetes and the
development of new therapies to restore natural insulin production.
“Living Window” Allows Scientists to
View Cell Activity in Real Time
We now have a view into cellular functions like
never before. For the first time, our scientists can
actually observe insulin-secreting cells inside
the living organism.
This viewing platform also gives us a way to watch
the body’s response to new therapeutic strategies
that attempt to save islets from this deadly
immune system attack.
Measuring Islet Viability with
Calcium Signals
In 2009, in collaboration with the Karolinska
Institute in Stockholm, Sweden, we transplanted
islets into the eye of a mouse, and then viewed
the islets through the animal’s transparent cornea.
Through this “living window,” we watched the islets
engraft onto the iris, connect to a network of blood
vessels, respond to stimulation and actually reverse
diabetes in the animal.
One way to measure the health and viability of
islets, prior to transplantation, is to track signals
sent by calcium within each cell. When glucose
reaches a beta cell, a sequence of events is triggered.
As part of the sequence, calcium within the cell
sends a signal that allows insulin to be released.
The stronger the calcium signal, the greater the
insulin response.
Using this novel, non-invasive technology, we can
see how the immune system launches its attack
on the islets cells, something that occurs in the
natural course of type 1 diabetes onset.
We’re now measuring those calcium signals because
by doing so, we believe we can identify islets that
are the healthiest and are most likely to survive.
Nephrin, a known target of
immune attack in type 1 diabetes,
is expressed in pancreatic beta
cells (green). When stimulated by
glucose, it acts as a major regulator
of insulin release (red) - opening
the door for the development of
therapeutic strategies targeting
nephrin to preserve cell function in
diabetes and islet transplantation.
Newly-Discovered Pancreatic Molecule Vital to Insulin Secretion
Recent findings suggest there might be a link between the development of diabetes and a molecule called
nephrin. Nephrin is a substance essential for optimal kidney filtration, which eliminates toxins produced by
the body. Although nephrin was once thought to be a kidney-specific molecule, we recently discovered it in
the pancreas and are now working to understand the role it plays in diabetes.
Our preliminary research, funded through donations made to the Diabetes Research Institute Foundation,
shows the nephrin molecule is vital for beta cells to secrete insulin in response to blood sugar. Nephrin may
also be a target of immune system attack in persons with type 1 diabetes.
With that preliminary data in hand, we secured funding this year from the National Institutes of Health
and the American Diabetes Association to continue this promising research. Our goal now is to better
understand the connection between nephrin and the function of insulin-producing cells in those with
diabetes. Once that connection is clear, the development of drugs targeting nephrin may represent one
approach to the treatment of diabetes.
A summary of our preliminary research on nephrin was published in October, 2009 in the journal Diabetes.
11
Predicting Diabetes Onset
Our Immunogenetics and Molecular Biology teams are leading a study of tiny nucleic acid molecules, called
MicroRNA, which may be used to predict the onset of diabetes. These molecules regulate key biological
processes in our bodies such as cell growth and the development of stem cells into functional adult cells.
These MicroRNAs also regulate key immune functions.
Our preliminary studies indicate patients with type 1 diabetes have a dramatic increase in one of these
regulators, miRNA-7, compared to their family members who do not have the disease. As a biomarker,
miRNA-7 may help us detect islet autoimmunity very early, increasing the probability of success in treating
or preventing the disease.
The study is now recruiting additional families as part of an ancillary study of the National Institutes
of Health’s Type 1 Diabetes TrialNet. TrialNet is a consortium of clinical centers with additional collaborating
centers in Canada, Italy, Germany, Finland and Australia. The goal of the study is to identify people at risk
for developing diabetes and to slow disease progression in people newly diagnosed
with the disease.
SOURCES OF INSULIN PRODUCING CELLS AND REGENERATION
One of the most critical challenges we face is to develop sources of insulinproducing cells. We believe stem cells could be used to alleviate the shortage of
insulin-producing cells available for transplant. Stem cells reproduce quickly. They
have the potential to become any cell type of the body and are simply waiting for
“instructions” to be programmed into one tissue or another. During 2009, much
of our research has focused on developing safe, efficient protocols for the use of
stem cells; work made possible through the generosity of private donors. But
our team of scientists at the DRI is also aggressively pursuing other sources of
insulin-producing cells, including the use of adult skin and cord blood cells,
transdifferentiation (reprogramming one cell type to grow into another) and
regeneration (generating new insulin-producing cells from one’s own tissues).
Making Embryonic Stem Cell Use Safer
We continue to make progress in our goal to eliminate
risk associated with the use of embryonic stem cells as
a potential therapy for diabetes.
Embryonic stem (ES) cells are immature cells that
proliferate at a remarkable rate. Their ability to multiply
makes them an ideal candidate to alleviate the shortage
of insulin-producing cells in persons with diabetes.
When left unchecked, however, wildly dividing ES cells
can cause tumors to form. We are working to eliminate
that risk by developing safer, more efficient protocols
for the use of ES cells.
One strategy is to provide ES cells, being cultured in the
lab, with high levels of oxygen. We believe the oxygen
helps speed the transformation – or differentiation –
of the ES cells into insulin-producing cells. Once
differentiated, the cells stop dividing.
13
A second strategy involves the use of protein
transduction technology (PTD) to induce the
differentiation. Embryonic stem cells proceed through
five developmental stages in order to become insulinproducing cells. At each stage, a “developmental switch”
needs to be turned on to drive the cell down the
intended path. The key is to insert these developmental
switches, or signals, safely into the cell. We are using
proteins to deliver these signals and sequentially
orchestrate the development of islet cells. This protein
therapy is believed to be safer and more efficient
than gene therapy – making it a more likely candidate
for clinical trials.
Reprogramming a Person’s Own Cells
Our pioneering efforts in protein transduction technology (PTD) are also being used as a safer method
for reprogramming existing adult cells into insulin-producing cells.
Research has already demonstrated that a person’s own skin cells, for example, can be returned to an
undifferentiated state, similar to that of an embryonic stem cell, then reprogrammed to become an insulinproducing cell. Now, our researchers are studying the use of proteins to induce that transformation more
safely than ever. The results of this preliminary work, funded by the Diabetes Research Institute Foundation,
were so encouraging, the National Institutes of Health awarded us a grant this year allowing us to further
explore the potential of this technology.
Cord Blood Cells
Umbilical cord blood cells are also showing promise as a potential source of insulin-producing cells. Cord blood
stem cells, as the name implies, are derived from newborn umbilical cord blood. Studies have suggested that
these cells can be coaxed into becoming cells that have features common to insulin-producing beta cells.
At the DRI, we are exploring the true potential of these cells.
We have already established the conditions that are necessary to culture these cells with reproducible success.
Now, we are working to improve the protocols used to transform, or differentiate, these cells. We are studying
the use of protein transduction technology (PTD) to induce the differentiation. Compared to gene therapy,
PTD offers a safer and more efficient method to orchestrate the development of a stem cell. We’re also
researching the use of various materials, such as bioengineered scaffolds, to provide physical support to
the cells as they mature.
Mesenchymal Stem Cells
Dr. Norma Sue Kenyon, co-director of the Executive Research Council at the Diabetes Research Institute,
and her team continue to develop ways to replace insulin-producing cells without the need for life-long
anti-rejection drugs. A major research focus is to improve islet survival by preventing the inflammation that
occurs when the cells are transplanted and exposed to other environmental factors. Dr. Kenyon and her team
are using a population of bone marrow derived mesenchymal stem cells (MSCs) to achieve this. These cells
have been instrumental in repairing damaged tissue and have also shown the ability to stimulate the
growth of blood vessels as well as significantly reduce inflammation. These are two critical areas needed for
successful islet replacement strategies and are the basis for studies involving the co-transplantation of both
islets and MSCs. In addition to enhancing graft acceptance and longer term viability of the new cells, MSCs
produce factors that help suppress the immune response to transplanted cells and may also support the
production of new insulin-producing cells.
Transdifferentiation
Our researchers are testing the ability to turn cells that have a different
function into insulin-producing cells, a process known as transdifferentiation.
Our study of transdifferentiation focuses on liver cells. The liver and the
pancreas, where insulin-producing islet cells develop naturally, have a
lot in common. They start off – in the earliest stages of development –
as the same kinds of cells. Some branch off to form the liver; others,
the pancreas. To take advantage of the two organs’ developmental
similarities, we are working to coax a population of liver cells into
insulin-producing cells. We’re partnering on this effort with
Lola M. Reid, PhD, professor in biomedical engineering at the University
of North Carolina, who has been a leading researcher on liver stem
cells for more than 30 years.
If successful, this transdifferentiation from liver to pancreatic cells would
allow a patient with diabetes to be the donor of his/her own therapeutic
tissue. The potential to effectively generate new tissues from our own
mature organs would overcome both the shortages in tissue availability
and the need for immunosuppression, or anti-rejection drugs.
15
Regrowing Our Own Insulin-Producing Cells
There is mounting evidence the body may be able to regenerate or “regrow” insulin-producing cells
through a natural, self-repairing process. At the Diabetes Research Institute, we’re studying whether
this cell regeneration process has the potential to reverse or prevent the onset of type 1 diabetes.
Our scientists and their colleagues are testing several methods to stimulate islet regeneration in the native
pancreas. These approaches include the use of hepatocyte (HGF) and epidermal growth factors (EGF) along
with hormones such as Gastrin, among others.
If an abundance of healthy islets can be regenerated early on, then this could eliminate the need for islet
transplants altogether.
Molecule May Increase Number of Insulin-Producing Cells
As we explore new ways to increase the number of insulin-producing cells, our researchers are also
studying the properties of molecules called MicroRNA.
MicroRNAs are tiny nucleic acid molecules that regulate key, biological processes in our bodies such as cell
growth and the development of stem cells into functional, adult cells. A team of researchers here at the DRI
identified one such regulator, called miRNA-7, which appears 200 times more frequently in insulin-producing
islets than in other non-islet tissue of the pancreas.
As a result, miRNA-7 is believed to be involved in expanding the number of islets and increasing insulin
production. By better understanding miRNA-7 and the role it may play in promoting cell expansion and
regulating insulin production, we may identify new strategies for clinical therapies in the treatment of diabetes.
NANOTECHNOLOGIES, ENCAPSULATION, BIOMATERIALS, DEVICES
AND LOCAL DRUG DELIVERY
Along with the need to develop new sources of insulin-producing cells, we must
identify new ways to improve islet transplant technology and the body’s ability
to tolerate those transplanted cells. To meet that challenge, we’ve brought
together researchers from such diverse disciplines as engineering, immunology,
biomaterials and computer technology to work together, and in 2009, these
multi-disciplinary teams have made exciting progress that takes our pioneering
work in traditional cell-based science to a new level.
Biohybrid Devices
In a recent study, our researchers designed and
implanted a small mesh cylinder under the skin
(subcutaneous) to house and protect transplanted
cells. Once a network of blood vessels grew in and
around the mesh, islet cells were inserted into
the cylindrical “biohybrid device” and the alreadyestablished blood vessels were able to immediately
deliver oxygen and other vital nutrients to the cells.
These self-contained devices act as mini “organs”
and have been engineered to provide islet cells
with an enhanced ability to thrive. But they offer
another benefit. The device gives researchers the
opportunity to deliver tiny amounts of anti-rejection
drugs precisely where the cells are located;
eliminating the systemic drugs used today which
cause so many unwanted side effects. As a result, in
experimental models, just 1/100th of the amount of
anti-rejection drugs was required, minimizing side
effects for the transplant recipient.
This past year, we began to focus on developing new
and improved strategies for the delivery of agents
to these implantable devices, to further shield
transplanted islets from attack. Moving forward,
the goal is to develop an environment that mimics
the native pancreas as much as possible so that
transplanted insulin-producing cells have the
best chance to thrive.
17
A strong outer frame protects the
islets from physical damage. An
open mesh membrane promotes
the growth of blood vessels inside
the device to nourish the islets with
oxygen and nutrients in a highly
porous structure shown.
[
Visit our web site to hear
a podcast on scaffolds from
Dr. Cherie Stabler
Bioengineered “Scaffolds”
In another example of how we’re applying technology to enhance traditional science, our tissue engineering
team is testing new strategies for the use of bioengineered “scaffolds.” Much like the scaffolding you’d see
on the outside of a building, these bioengineered scaffolds, developed at the DRI, provide a 3-dimensional
framework to protect islet cells. Like the biohybrid devices, the scaffolds help to mimic the native environment
of the pancreas by preventing islets from clumping together, allowing oxygen and other nutrients to efficiently
reach each cell.
Now, we are initiating studies to see if the scaffolds could also be used to deliver beneficial cells or agents
that will further increase the viability of transplanted islets. One strategy incorporates an oxygen-generating
compound to the scaffolds which has resulted in improved islet viability and glycemic control in study animals.
A second strategy involves co-delivering other cells that will accelerate vascularization, the growth of blood
vessels in and around the scaffold.
The DRI's Dr. Cherie Stabler is one of 10 scientists nationwide who have won the Type 1 Diabetes Pathfinder
Award for highly innovative research studies that offer exceptional promise for improving the understanding,
prevention, and treatment of type 1 diabetes and its complications.
The Pathfinder Award supports creative new investigators who propose innovative research projects that have
the potential for unusually high impact in type 1 diabetes. Each award recipient receives $1.5 million to pursue
their work over a five-year period.
Microscopic Encapsulation Technology Protecting Transplanted Islet Cells
In 2009, our researchers continued to report signs of success in the development of nanoencapsulation
technology, the newest area of immunoisolation research.
Nanoencapsulation is a microscopic layering technique that’s been used for decades in the electronics,
optics and sensor industries. By adapting this methodology to cell-based science, researchers are developing
biocompatible coatings that serve as a type of “camouflage” for the implanted islets, allowing them to go
unnoticed by the body and avoid inflammatory reactions or immune attack. And, because the nanoencapsulation
layer is so thin – almost as if it’s “shrink-wrapped” around the islet cells – oxygen and nutrients can easily reach
the cells and the islets themselves can efficiently release insulin back into the bloodstream. Additionally, in
contrast to previously-used coating methods, nanoencapsulation helps to maintain the actual size of the cell
so that more cells can be transplanted into a smaller space.
Along with protecting the cell, researchers believe these nanoscale layers can also be made “active.”
By attaching anti-inflammatory molecules to their surface, the nanoscale layers actively ward off attacks on
the transplanted cell.
Because this nanoencapsulation strategy holds such promise, we’ve established a partnership with Dr. Jeffrey
Hubbell, professor and director of the Integrative Biosciences Institute, and Professor of the Institute for
Chemical Sciences and Engineering at Ecole Polytechnique Fédérale de Lausanne in Switzerland. Dr. Hubbell
is world renowned for his work with biomaterials for tissue engineering and drug delivery.
19
Bone Marrow as a Site
In addition to bioengineering environments that mimic the pancreas, DRI researchers are studying
whether other sites within the body may be used to successfully house transplanted cells.
For years, the liver was thought to be the optimal environment for transplanted insulin-producing cells to
survive. But in the past decade, there has been mounting evidence to the contrary – and researchers are
now looking for alternative transplant sites.
In preliminary animal studies conducted by the DRI in conjunction with Hospital San Raffaele in Italy, one of
the members of the global research collaboration known as the Diabetes Research Institute Federation, islets
were infused into the bone marrow of mice. Bone marrow is the soft, spongy tissue found inside bones, where
95 percent of the body’s blood cells are developed and stored. The results show the approach is safe and
potentially suited for clinical trials.
IMMUNOMODULATION AND TOLERANCE
As we continue to develop a supply of insulin-producing cells and identify
optimal environments within which they can thrive, scientists still need to
re-educate the body to tolerate these cells; to see them as “self” and allow
them to exist. Currently, islet transplant recipients must take powerful
immunosuppressant drugs for life. These drugs often cause unwanted side
effects, including damage to the islets themselves. One area of focus for
us during the past year has been to pursue approaches to limit the use
of immunosuppressants, to make them less harmful to the recipient, to
deliver them only where they’re needed, and to eliminate them altogether.
Drug Discovery Program
One of the most exciting developments in this area of research during the past year came from our
Drug Discovery team, led by Peter Buchwald, Ph.D. The team demonstrated that small molecules might
help block a critical pathway used by the immune system when it attacks insulin-producing cells.
We’ve been investigating for some time this particular pathway, known as the CD40-CD154 pathway, to
determine if we can interfere with the cascade of events that leads to transplant rejection by the recipient's
immune system. Previously, we demonstrated that it was possible to block the pathway in pre-clinical
models with an antibody to the CD154 molecule, but blood clots developed in 10 percent of the cases and
the drug was removed from clinical development.
Further research, conducted by the Drug Discovery team during the past year, shows that instead of
the antibody, a small molecule may instead be used to block the pathway – and without the blood
clot side effects.
The team’s research findings were published in the Journal of Molecular Medicine 2009.
That Drug Discovery team is also working with our Tissue Engineering group to develop methods to deliver
immunosuppression to the local transplant site. Instead of using systemic drugs that affect the entire body,
the collaborative team is developing a system to provide safer, low-dose drugs directly into an implanted
device containing the insulin-producing islets.
21
[
Visit our web site to hear
a podcast on T Regulatory
Cells by Dr. Thomas Malek
Bioengineering Tolerance with Nanoparticles
One of the newest and most quickly evolving fields of bioengineered medicine involves the study and use
of nanoparticles, synthetic materials that are microscopic in size; thousands fit inside the width of a single
human hair. We are studying whether these microscopic particles can be used to help patients tolerate
transplanted insulin-producing cells.
Under the direction of Dr. Jeffrey Hubbell, we are developing ways to use nanoparticles to carry tiny
amounts of anti-rejection drugs to key parts of the body’s immune system. The belief is that because these
nanoparticles are so small, they can be sent precisely to cells in the body that regulate the immune system’s
response. By pinpointing the delivery of the drug to a specific cell, we can potentially dampen or modify an
immune response that would be triggered by the introduction of foreign tissue and allow patients to
tolerate transplanted insulin-producing cells.
Using the Body’s Immune System Cells to Achieve Tolerance
Along with pursuing tolerance through the development of bioengineered medicine, we are looking for
ways to re-educate the body’s immune system to recognize and accept insulin-producing cells.
There are cells within our own bodies whose job is to constantly scan and rescan the tissues of the body,
evaluating what they see. If these cells notice something foreign or out of balance within the body, they
have the capacity to trigger the immune system to respond. And in some cases, they have the capacity to
suppress a response.
Along with our colleagues at Hospital San Raffaele (DRI Italy), we’ve identified a way to isolate one such cell,
the Regulatory T Cell (or TReg), from a patient’s own blood. As the name implies, TRegs regulate the function
of the immune system and prevent uncontrolled reactions by suppressing immune responses. In people with
type 1 diabetes, there’s an imbalance of these TRegs which leads to the destruction of insulin-producing
cells in the pancreas. Our scientists are developing strategies to restore that balance of Regulatory T Cells.
Another naturally-occurring cell we’re studying is the Marrow Derived Suppressor Cell, or MDSC. MDSCs
accumulate in certain areas of the body and we believe they could be used to teach the body to either
tolerate its own insulin-producing cells or tolerate transplanted insulin-producing cells. In 2009, we began
to evaluate the effects of MDSCs on autoimmunity and transplant rejection.
Hyperbaric Oxygen Therapy
There is increasing evidence that oxygen plays a critical role in the development and viability of insulinproducing cells. We are pursuing several strategies to more efficiently deliver oxygen to these cells,
including the use of hyperbaric oxygen therapy, or HOT.
HOT has been used for decades to deliver pressurized oxygen to scuba divers who suffer complications
after being underwater. It is a remarkably simple, non-invasive therapy that is showing early signs of
promise in diabetes research. In pre-clinical studies conducted by DRI scientists, animals that received
hyperbaric oxygen therapy were 50 percent less likely to develop diabetes than those without HOT. The
preliminary data showed such potential our researchers presented their findings at the American Diabetes
Association Meeting in May, 2009.
Clinical trials are currently underway at the Diabetes Research Institute where patients are being given a
combination of oxygen treatments along with infusions of their own bone-marrow derived stem cells. The
hope is that the combined treatments will cause the pancreas to either recover or function well enough to
allow patients to significantly decrease or stop their medications. Similar trials will take place in Europe,
Asia and Latin America as part of the collaborative efforts of the DRI Federation.
23
Clinical Trials
Our Clinical Cell Transplant Program (CCTP) continues
to build on the promising results of a landmark
multi-center clinical trial which demonstrated that
patients with long-standing diabetes could achieve
insulin independence following infusions of
insulin-producing islet cells.
The results, published in the 2006 American Journal
of Medicine, concluded that while nearly 90 percent
of the study participants were able to discontinue
insulin injections during the first year, over time the
transplanted islets lost function, requiring most
patients to resume low doses of insulin. Despite
needing insulin again, the patients maintained
some insulin production from the transplanted
islets, allowing for easy-to-manage blood sugars
and, most importantly, without experiencing
episodes of hypoglycemia.
Within the past 24 months, we published a follow up
study, “Improved long-term health-related quality
of life after islet transplantation.” In that study, 40
islet recipients were followed for seven years and it
was concluded that islet transplantation is associated
with long-term improvement in quality of life.
In other recent developments, our clinical trials
have demonstrated:
• The improved metabolic control achieved with
islet transplantation can restore hypoglycemia
awareness in patients with type 1 diabetes,
persisting even after islet graft failure.
• When combined with islet transplantation, two
new drugs, Exenatide and Etanercept, improve
engraftment and long-term islet survival
and function.
• Kidney function remained stable after islet
transplantation alone in our studies.
Our steady progress in this field justifies a renewed
optimism for the potential of cellular therapies
in diabetes. As the current limitations of islet
transplantation are progressively overcome, the
indication for clinical applicability of these strategies
will greatly expand to more widely available cellular
therapies and regenerative medicine solutions that
will eventually be offered as treatment to the majority
of patients with insulin-requiring diabetes. In 2009,
we reviewed the “Steady Progress and Current
Challenges in Clinical Islet Transplantation” in
Diabetes Care.
We continue to focus on improving the safety and
long-term success of cell replacement therapies.
The Clinical Cell Transplant Program has several
active protocols that will assess the effectiveness
of new drugs to prevent rejection, as well as other
agents to improve islet engraftment and increase islet
mass after transplantation. In addition, the group is
identifying markers that indicate early islet loss as
a means of developing intervention strategies to
sustain islet function.
We are actively screening individuals for participation
in the islet alone or islet after kidney transplantation
studies. For additional information on the trials and/or
eligibility criteria, please call 305-243-5321 or visit:
DiabetesResearch.org/clinicaltrials.
Trial Net
Six Diabetes Research Institute investigators assumed
leadership roles in 2009 with the Type 1 Diabetes
TrialNet. Funded by the National Institutes of Health,
TrialNet is a consortium of clinical centers that enables
researchers around the world to perform intervention
studies aimed at preserving insulin-producing cells in
individuals with newly-onset diabetes, or in those at
risk of developing the disease.
Under the direction of the DRI’s Jay Skyler, M.D., TrialNet
national chairman, we’re currently participating in a
number of TrialNet studies, which can be found at
DiabetesTrialNet.org
and patients receive prompt feedback when
inquiring about our services.
•
We’ve developed and implemented an Electronic
Data Management System (EDMS) to capture
essential demographic, education and clinical
outcomes data of patients attending the Diabetes
Education Service. We have over 1,200 patients
entered into the system and have captured to
date over 4,000 education visits. We presented
the EDMS at the 2009 American Association of
Diabetes Educators National Symposium and
plan to export the system to other diabetes
health care services in 2010.
•
We developed 15 Education Factsheets, available
in both English and Spanish, as part of our Mastering
Your Diabetes program. Mastering Your Diabetes is
a five-day intensive insulin management program
that is offered four times per year, with a specific
program for children held each summer. The program
aims to enhance participant knowledge and
problem-solving skills across insulin management
and blood glucose monitoring to optimize diabetes
control and health outcomes. Our new fact sheets
are available on the DRI web site and will be provided
to our key community referrers and utilized at
community health fairs.
•
We continue to provide and review areas of
strength and potential growth across our 13 monthly
group education programs. Our group programs,
conducted in English and Spanish, cover all key
content areas from basic diabetes and nutrition
information (Diabetes Made Simple, Domine La
Diabetes, Supermarket Shopping) through to insulin
management programs (Basal / Bolus Insulin
Therapy and Carbohydrate Counting) and advancing
to insulin pump therapy and continuous glucose
monitoring programs.
In 2009, we also published the results of one trial where
we concluded the drug rituximab helped to preserve
beta cell function over a period of one year in patients
with type 1 diabetes. The findings were published in the
November 26, 2009 New England Journal of Medicine.
Our TrialNet researchers include Dr. Jay Skyler, TrialNet
national chairman; Dr. Norma Sue Kenyon, associate
chair for immunology; Dr. Jennifer Marks, principal
investigator – TrialNet Clinical Center; Lisa Rafkin-Mervis,
study co-chairman; Dr. Alberto Pugliese, co-investigator,
clinical center and Della Matheson, trial coordinator.
Patient Education Service
One of the greatest challenges facing people living
with diabetes is their ability to gain awareness of and
implement the necessary self-management demands
expected of this disease. The Diabetes Education Service
of the DRI’s Eleanor and Joseph Kosow Diabetes
Treatment Center is designed to support that need for
timely and effective education. This year, our patient
education initiatives were once again awarded the
highest standards of recognition with the American
Diabetes Association’s Education Recognition Program
(ADAERP) certification.
We’re proud of our accomplishments over the past
18 months:
•
We have enhanced communications with referral
sources (resulting in an increase of our external
referral base from 13 to 51 referrers), created new
collaborations and taken steps to make sure referrers
25
Throughout 2010 we will continue to focus on existing
education programs, the development of new education
initiatives to meet patient needs and ongoing team
development and diversification. Collaboration,
innovation, integration and evaluation will continue
to be the driving force of our education service.
faculty
[and staff
listing]
Faculty
Dr. Camillo Ricordi
Dr. Luca Inverardi
Stacy Joy Goodman Professor of Surgery
Distinguished Professor of Medicine
Director, Diabetes Research Institute and
Cell Transplant Center
Research Professor of Medicine, Microbiology
and Immunology
Director, Immunobiology of Islet Transplantation
Associate Director, Cell Transplant Center
Dr. Rodolfo Alejandro
Dr. Norma S. Kenyon
Professor of Medicine
Associate Director of Clinical Research
Associate Director, Cell Transplant Center
Director, Clinical Cell Transplant Center (CCTP)
Martin Kleiman Professor of Surgery, Medicine,
Microbiology and Immunology and Biomedical Engineering
Director, Wallace H. Coulter Center For Translational Research,
University of Miami
Dr. Anthony Atala
Dr. Livio Luzi
Adjunct Professor
W.H. Boyce Professor and Director of the Wake
Forest Institute for Regenerative Medicine
Wake Forest University School of Medicine,
Winston-Salem, NC
Adjunct Professor
Professor of Physiology
Director, Amino Acid and Stable Isotopes Laboratory, Nutrition
and Metabolism Program
University of Milan, San Raffaele Scientific Institute, Milan, Italy
Dr. Allison Bayer
Dr. Thomas Malek
Research Assistant Professor
Professor and Vice-Chair of Microbiology and Immunology
Dr. Per-Olof Berggren
Dr. Luz Prieto-Sanchez
Mary Lou Held Visiting Scientist
Adjunct Professor of Surgery
Head of Cell Biology and Signal Transduction
Professor and Head, Experimental
Endocrinology at the Karolinksa Institute in Sweden
Assistant Professor of Clinical Medicine,
Division of Endocrinology, Diabetes and Metabolism
Dr. Jennifer Marks
Research Associate Professor of Surgery
Interim Chief, Division of Endocrinology,
Diabetes and Metabolism
Medical Director of the Miami VA Medical Center
Dr. Peter Buchwald
Dr. Armando Mendez
Assistant Professor
Department of Molecular and Cellular Pharmacology
Director, Drug Discovery Program
Associate Professor of Medicine,
Dr. Dora Berman-Weinberg
Dr. Luigi Meneghini
Dr. Zhibin Chen
Assistant Professor, Department of
Microbiology and Immunology
Associate Professor of Clinical Medicine
Director, Eleanor and Joseph Kosow Diabetes Treatment Center
Dr. Shari Messinger
Dr. Juan Dominguez-Bendala
Assistant Professor of Epidemiology and Public Health
Director, Stem Cell Development for Translational Research
Dr. Daniel H. Mintz
Dr. Sarah Ferber
Scientific Director Emeritus
Visiting Professor
Head, Molecular Endocrinology Unit,
The Chaim Sheba Medical Center
Dr. Bresta Miranda-Palma
Assistant Professor of Medicine, Division of
Endocrinology, Diabetes, and Metabolism
Dr. Alessia Fornoni
Assistant Professor of Clinical Medicine,
Division of Nephrology and Hypertension
Dr. Ronald B. Goldberg
Director, Lipid Disorders Unit
Dr. Robin Nemery
Adjunct Professor of Pediatrics
Division Head of Pediatric Endocrinology at
Joe DiMaggio Children’s Hospital
Dr. Rajendra Pahwa
Medical Director, Human Cell Processing (cGMP) Facility
Dr. Jeffrey Hubbell
Adjunct Professor
Professor of Biomedical Engineering
Director, Integrative Biosciences Institute
Institute for Chemical Sciences and Engineering at
Ecole Polytechnique Fédérale de Lausanne, Switzerland
Dr. Ricardo Pastori
Research Professor of Medicine,
Immunology, and Microbiology
Director, Molecular Biology Laboratory
Dr. Maria del Pilar Solano
Assistant Professor of Medicine
27
Dr. Antonello Pileggi
Director, Pre-Clinical Cell Processing and
Translational Models
Dr. Alberto Pugliese
Research Professor of Medicine,
Immunology and Microbiology
Director, Immunogenetics Program
Dr. Gennaro Selvaggi
Assistant Professor of Clinical Surgery,
Liver and Gastrointestinal (GI)
Dr. Jay Skyler
Professor of Medicine, Pediatrics and Psychology
Associate Director of Academic Programs
Chairman, NIDDK Type 1 Diabetes TrialNet
Study Group
Dr. Cherie Stabler
Assistant Professor of Biomedical Engineering
Director, Tissue Engineering Laboratory
CCTP Research and Support Staff
Andrea Curry, Advanced Registered Nurse Practitioner
Eva Herrada, Manager, Research
Alina Cuervo, Sr. Medical Biller
John Wilkes, Sr. Regulatory Analyst
Vincenzo Lauriola, Research Associate
Dr. Karina Bernetti, Post Doctoral Associate
Dr. Eduardo Leão M. Peixoto, Post Doctoral Associate
Edwin Cintron, Office Manager
Yanet Florez, Secretary
Alina Cuervo, Sr. Medical Biller
Lilian Ali, Data Entry Clerk
Cecilia Arana, Data Entry Clerk
Tyeisha Burford, Research Laboratory Tech
Kyla Zehtab, Research Assistant
Clinical Chemistry
Dr. Ronald B. Goldberg, Professor of Medicine
Espy Perez, Supervisor, Medical Technology
Dr. Armando Mendez, Research Associate Professor
Rosa Hernandez, Sr. Research Lab Tech
Jorge Montelongo, Sr. Cellular Transplant Specialist
Dr. Andreas Tzakis
Professor and Director, Miami Transplant Institute
Director of Microsurgery Core Facility in
the Cell Transplant Center
Chief of the Division of Liver and
Gastrointestinal (GI) Surgery
Dr. Keith Webster
Clinical Research Center
Dr. Luigi Meneghini, Director
Dr. Claudia Ardila, Post-Doctoral Associate
Ada Konwai, Sr. Patient Clinical Assistant
Burlett Masters, Research Support Specialist
Diane Sabogal, Sr. Medical Assistant
Professor, Molecular and Cellular Pharmacology
Administration
Dr. Mitra Zehtab, Chief Operating Officer
Sabrina Boulazreg, Assistant Operations Manager
Mabel Luis, Executive Assistant to Dr. Ricordi
Margaret Collado, Chief Financial Officer
Anjanette Arzani, Manager, Finance
Dora Cardenal, Manager, Accounting
Juan Perez-Scholz, Manager, Sponsored Programs
Caridad Bassols, Program Coordinator
Franlis Alvarez, Bookkeeper
Edmundo Caldera, Accounting Assistant
Ligia Delgado, Accounting Assistant
Marc Friedenthal, Buyer
Grace Perez, Sr. Buyer
Ilvis Torres, Administrative Assistant
Jeanette Shikak, Administrative Assistant
Medical Development
Gary Kleiman, Sr. Development Director, Major Gifts
Aimee Siegel-Harris, Manager, Donor Relations
Cell Biology and Signal Transduction
Dr. Per-Olof Berggren, Director
Dr. Midhat Abdulreda, Research Scholar
Dr. Alberto Fachado, Sr. Research Associate
Rayner Rodriguez-Diaz, Research Associate
Clinical Cell Transplant Program (CCTP)
Dr. Rodolfo Alejandro, Director
Dr. Livio Luzi, Adjunct Professor of Surgery
Dr. Raffaella Poggioli, Assistant Scientist
Dr. Gennaro Selvaggi, Assistant Professor of Surgery
Diabetes Prevention Program (Type 2)
Dr. Ronald B. Goldberg, Director
Dr. Hermes Florez, Assistant Professor of Clinical Medicine
Jeanette Gonzalez-Calles, Research Associate
Juliet Ojito, Nurse Specialist
Dr. Sumaya Castillo Florez, Assistant Scientist
Wanda Ramirez, Secretary
Bertha Veciana, Medical Assistant
Drug Discovery Program
Dr. Peter Buchwald, Director
Dr. Emilio Margolles Clark, Assistant Scientist
Eleanor and Joseph Kosow Diabetes Treatment Center
Dr. Luigi Meneghini, Director
Dr. Ronald B. Goldberg, Professor of Medicine
Dr. Jennifer B. Marks, Professor of Medicine
Dr. Daniel H. Mintz, Professor of Medicine
Dr. Bresta Miranda-Palma, Assistant Professor of Medicine
Dr. Luz Prieto-Sanchez, Assistant Professor of Medicine
Dr. Anup Sabharwal, Assistant Professor of Medicine
Dr. Jay S. Skyler, Professor of Medicine, Pediatrics and Psychology
Dr. Maria del Pilar Solano, Assistant Professor of Clinical Medicine
Health Care Professionals
Ramon Arce, Sr. Registered Nurse
Alejandra Cordovez, RD, LD/N, CNSC
Kellie Rodriguez, Manager, Nursing
Jane Sparrow-Bodenmiller, Registered Nurse Educator
Allison Wick, Advanced Registered Nurse Practitioner
Clinic Administration
Angela Almestica, Patient Clinical Associate
Michael Amada, Sr. Staff Assistant
Arleen Barreiros, Sr. Administrative Assistant
Hariamnys Caceres, Patient Clinical Assistant
Odalys Cano, Patient Access Representative
Iliana Gonzalez, Patient Access Representative
Jannet Fraguela-Yern, Clinic Manager
Hector Villagran, Sr. Patient Clinical Assistant
Flow Cytometry Facility
Dr. Oliver Umland, Associate Scientist
Human Cell Processing (cGMP) Facility
Dr. Rajendra Pahwa, Medical Director
Aisha Khan, Director of Laboratory Services
Alejandro Alvarez Garcia, Associate Scientist
Dr. Shashidhar Jaggaiahgari, Post-Doctoral Associate
Dr. Elina Linetsky, Director, Quality Assurance/Regulatory Affairs
Dr. Omaima Malik, Associate Scientist
Dr. Joel Szust, Scientist
Dr. Xiaojing Wang, Associate Scientist
Xiumin Xu, Manager, Cord Blood Program/
Flow Cytometry Clinical Lab
Kevin Peterson, Sr. Cellular Transplant Specialist
Carmen Castillo, Research Laboratory Technician
Judith Molina, Sr. Research Associate
Maite Lopez Cabezas, Research Associate
Yelena Gadea, Specialist
Irayme Labrada, Specialist
Elsie Zahr, Sr. Research Associate
Pre-Clinical Research and Program Development
Dr. Norma S. Kenyon, Director
Dr. Dora Berman-Weinberg, Research Associate Professor
Waldo Diaz, Manager, Research Laboratory
James Geary, Veterinary Tech
Dr. Dongmei Han, Scientist
Ena Poumian-Ruiz, Supervisor, Research Laboratory
Reiner Rodriguez-Lopez, Veterinary Technician
Laura Velez, Sr. Administrative Assistant
Research Staff
Dr. Ana Hernandez, Post-Doctoral Associate
Alexander Rabassa, Research Associate
Melissa Willman, Senior Research Associate
Cellular Medicine
Dr. Alessia Fornoni, Assistant Professor of Clinical Medicine
Dr. Nancy Jauregui-Aguirre, Post-Doctoral Associate
Maria Saenz, Sr. Research Associate
Jongmin Jeon, Research Associate
Tammy Suwunrut, Sr. Administrative Assistant
Stem Cell Development for Translational Research
Image Analysis Facility
Dr. George McNamara, Scientist
Immunobiology of Islet Transplantation
Dr. Luca Inverardi, Director
Dr. Olakunle Adeegbe, Post-Doctoral Associate
Kevin Johnson, Sr. Research Associate
Dr. Ryosuke Misawa, Post-Doctoral Associate
Dr. Kamalaveni Prabakar, Scientist
Dr. Alessia Zoso, Research Associate
Rejane Lamazres, Research Associate
Immunogenetics Program
Dr. Alberto Pugliese, Director
Dr. Isaac Snowhite, Sr. Research Associate
Gloria Allende, Sr. Research Associate
Dr. Francesco Vendrame, Post-Doctoral Associate
Dr. Juan Domínguez-Bendala, Director
Dr. Sirlene Cechin, Post-Doctoral Associate
Dr. Nancy Vargas, Research Associate
Silvia Alvarez, Research Associate
Microbiology and Immune Tolerance
Dr. Tom Malek, Director
Dr. Allison Bayer, Assistant Professor
Cecilia Cabello, Research Associate
Tissue Engineering
Dr. Cherie Stabler, Director
Dr. Jeffrey Hubbell, Research Professor
Chris Fraker, Sr. Research Associate
Dr. Kerim Gattas-Asfura, Post-Doctoral Associate
Dr. Hernan Rengifo, Post-Doctoral Associate
Diabetes TrialNet
Molecular Biology
Dr. Ricardo Pastori, Director
Dr. Dagmar Klein, Scientist
Dr. Valia Bravo, Post Doctoral Associate
Dr. Margarita Nieto, Post-Doctoral Associate
Dr. Samuel Rosero, Associate Scientist
Pre-Clinical Cell Processing and
Translational Models
Dr. Antonello Pileggi, Director
Dr. Ann Brady, Post-Doctoral Associate
Dr. Carmen Fotino, Post-Doctoral Associate
Dr. Gaetano Faleo, Research Associate
Dr. Damaris Molano, Scientist
29
Dr. Jay Skyler, National Chairman
Dr. Norma Sue Kenyon, Associate Chair for Immunology
Dr. Jennifer Marks, Principal Investigator –TrialNet Clinical Center
Lisa Rafkin-Mervis, Study Co-Chairman
Della Matheson, Trial Coordinator
Dr. Alberto Pugliese, Co-Investigator, Clinical Center
about
[drif ]
MISSION: To provide the Diabetes Research Institute
with the funding necessary to cure diabetes now.
The Diabetes Research Institute Foundation was created in 1971 by a small group
of parents of children with diabetes who were committed to finding a cure for this
devastating disease. Driven by hope and fueled by the need to end their children’s
suffering, they banded together to support a promising research program at the
University of Miami solely aimed at curing those living with diabetes. This singular
goal remains today.
The Foundation has evolved into an international
coalition of business leaders, celebrities, research
scientists, clinicians, families and other concerned
individuals who have elevated the importance of
cure-focused research and shifted the direction of
funding into this critical area.
The DRI has become the world leader it is today
through the dedication and perseverance of the
people involved with the Foundation – those who
have a personal stake in the eradication of this
disease. Supported by private philanthropy, the
DRI Foundation has been and continues to be the
organization of choice for those who are serious,
passionate and committed to finding a cure for their
loved ones and millions of others with diabetes.
Over the years, thousands of generous individuals
and companies have given of their time and
resources to help fulfill the DRI’s mission. One
of the Foundation’s most faithful partners is the
Building and Construction Trades Department
(BCTD) of the AFL-CIO, whose members have raised
millions of dollars to construct and equip the DRI
facility, dedicated in 1994, and who continue to
fund its vast research initiatives.
Through a special program called the Blueprint for
Cure, which dates back to 1984, the American labor
movement pledged its unwavering support of the
DRI’s mission to cure this disease. Building upon
their decades-long commitment, the BCTD has
strengthened their ongoing partnership with the
DRI through a new effort called Project Type Zero:
The hope for a diabetes-free tomorrow. Thanks to
the efforts of thousands of building and construction
trade members, millions of dollars have been
raised for the Institute's cure-focused research.
The leadership of the Foundation has also been
instrumental in voicing the plight of those with
diabetes in the public arena.
31
Together with other leading diabetes advocacy
organizations,the DRI Foundation has appeared
before Congress to request increased funding for
diabetes research, and has made recommendations
on the future direction of research appropriations.
On an annual basis, the Foundation hosts numerous
informational workshops for people with diabetes
and their families focusing on the latest advances
toward a cure. Additionally, Institute and Foundation
faculty and staff participate in a variety of print and
broadcast public service programs locally, nationally
and internationally, which are designed to educate
the community on current research progress and the
newest diabetes management techniques.
A 501(c)(3) not-for-profit corporation, the Foundation
raises funds through individual and corporate
donations, memberships, foundation grants, special
events, and planned giving, which allows donors
to leave a personal legacy by providing a gift in the
form of a will, trust or other deferred giving vehicle.
The DRI Foundation has thousands of members
both in the United States and around the world,
and has successfully expanded into various
locations, including the opening of regional
development offices in New York, Long Island
and Washington, D.C.
message
[chairman and
president]
This past fall, in conjunction with our Diabetes 2.0 Conference
in Florida, we toured a small group of presenters and attendees
through the Diabetes Research Institute. This sophisticated
group, comprised of members of the diabetes online community
and parents of children with diabetes, came prepared to ask a
myriad of questions.
What they were unprepared for were not only the
open and candid responses to their questions, but
the passionate determination to find a cure that
was palpable throughout their visit.
As one visitor wrote in his blog, “…it is obvious that
this group of people is obsessively focused on finding
a cure for diabetes…I was very impressed with the
way the institute is set up with the goal of finding
a cure as its core…”
And in the words of another, “When you are in the
room with these men and women who are working
everyday, all day, just to help you…it’s hard not to feel
overwhelming[ly] grateful and to think, ‘Wow, I really
am not alone in this.’”
Those statements ring true. We want to make it
perfectly clear that no one with diabetes is alone
because the DRI and Foundation are determined to
find a universal cure for this disease. Even through
the economic and fundraising challenges of the last
few years, we have not waivered because tomorrow
isn’t soon enough - we are working to find a cure for
diabetes now.
This past year, we’ve been fortunate to celebrate
some successes while also having to make some
sacrifices. After several years of substantial growth,
we’ve had to adjust to the realities of the economic
climate and, like most organizations, reduce our
budget and fine-tune our priorities. While the
majority of our assets were liquid and unaffected by
the financial collapse, we have raised far fewer funds
than initially anticipated. This reality forced us to
adopt a contingency plan that resulted in a reduction
of our financial allocation to the DRI by 25 percent.
Fiscal 2010 and 2011 will see continued reductions
absent a meaningful increase in fundraising.
As you will read in the Research Review section of
this report, Dr. Camillo Ricordi and his team have
responded to the challenging funding environment
by streamlining the scientific agenda to focus on
only the most promising initiatives. In doing so, they
have further enhanced the efficiency of the DRI’s
operation. The DRI’s efforts have been consolidated
into four primary research areas represented by
nearly 80 projects, a reduction from over 100 projects
a few years ago.
Coupled with support from the Foundation, peerreviewed grants from the National Institutes of
Health and other funding entities comprise a
meaningful portion of the Institute’s annual budget.
The DRI has always been one of the most highlyfunded diabetes centers given its cure-focused work,
however, many of these grants expired in the middle
of the year and, due to budgetary constraints, were
not renewed. Large grants, in particular, have been
the most difficult to secure.
It is a difficult time, but it also an exciting time. Our
researchers are digging into the deepest depths of
creativity, Leading with Vision and moving ahead
with determination to accomplish our goal.
At the Foundation, our number one focus remains
providing our scientists with the funds they need
to keep promising research moving forward and
maintaining the scientific program at the highest
level. We have had to work harder, smarter and more
Thomas D. Stern
Robert A. Pearlman
Chairman
President and Chief Executive Officer
resourcefully. Hence, we undertook a year-long
project to overhaul our website, DiabetesResearch.org,
so that we can better provide our visitors with updated
information, multimedia content, logical navigation,
easier donation and event registration forms, and a
new online community, DRInsider, that affords benefits
to those who join. Our new website was launched a
few months ago and we’re thrilled with the positive
feedback we’ve received. We encourage you to visit
the site, look around and join our community.
Along with the website, we’ve bolstered our Diabetes
Diplomats program. Supporters can now create their
own fundraising event(s) – either off line or online –
and right on our new site. Families and individuals
from around the country are spearheading events on
our behalf and these dollars have never been more
important. Our deepest thanks go to each and every
person undertaking an activity to benefit the DRI.
In addition to these generous individuals, a number
of companies have stepped to the plate to support
our efforts. Walgreens of South Florida launched a
campaign to help us “Cure Diabetes Now,” through
in-store canister collections, plush toy teddy bear
sales, and friendly competitions among hundreds of
employees in a company-wide softball tournament.
Their efforts have raised more than $100,000, to date,
with the campaign continuing into next year.
Walgreens, together with Johnson & Johnson’s Animus
and Lifescan divisions and numerous other companies
and families, served as sponsors of our Diabetes 2.0
Conference and their participation was sincerely
appreciated by the DRI, the Foundation and all of
our attendees.
Our Conference was but one of numerous events taking
place throughout our regions during the past year. The
involvement of a growing cadre of dedicated volunteers
helped to raise significant funds for the DRI, from golf
tournaments and galas to kid-friendly parties and
comedy night. All of the individuals who gave of their
time and resources should feel particularly proud of
what they’ve accomplished for this organization.
One of the largest groups raising funds on our behalf
is the Building and Construction Trades Department of
the AFL-CIO. Well into their new fundraising campaign,
Project Type Zero, the men and women of the unions
have stood alongside the DRI for almost four decades
and their commitment to our cause remains as strong
as ever. We are exceptionally grateful for their loyal
friendship and longstanding commitment to helping
us find a cure for this disease.
With thousands of dedicated and passionate people
supporting our efforts, we are certainly not alone.
As we pursue our mission to find a cure, we hope we
can count on your continued support, as it is more
important than ever before. Thank you again for the
generosity you have shown in the past and for what
you will continue to do in the future.
Thomas D. Stern
Robert A. Pearlman
Chairman
President and Chief
Executive Officer
financial
[statement]
Statement of Activities for
the Year ended June 30, 2009
Support and Revenue
Contributions
Reimbursement Contracts
Special Events, net of expenses
Investment Income
Total Support and Revenue
$4,308,011
2,003,723
2,933,878
(1,513,558)
7,732,054
Expenses and Fund Balances
Program Services
Research provided to the Diabetes
Research Institute
Community Education
11,984,866
749,024
Total Program Services
12,733,890
Through the support of private
philanthropy, the Diabetes Research
Institute Foundation has funded
six chairs totaling $14 million:
The J. Enloe and Eugenia J. Dodson
Chair in Diabetes Research,
Stacy Joy Goodman Chair in Diabetes
Research, Mary Lou Held Chair for
Diabetes Research, Martin Kleiman
Endowed Investigatorship,
Daniel H. Mintz Visiting Professorship,
and the Ricordi Family Chair in
Transplant Immunobiology.
Support Services
Administration and General
Fundraising
1,183,505
2,215,828
Total Support Services
3,399,333
Change in Net Assets
(8,401,169)
Net Assets, Beginning of Year
41,081,520
Net Assets, End of Year
$32,680,351
Fundraising Percentage
Fundraising Expense as a
Percentage of Support and Revenue
29%
Statement of Activities for the Fiscal Year 2009
Support
Diabetes Research Institute Foundation
$11,984,866
National Institutes of Health Grants
4,516,953
Kosow Center
2,398,564
Juvenile Diabetes Foundation International Grants 1,799,415
University of Miami
966,959
State of Florida
493,941
Corporate Grants
488,143
American Diabetes Association Grants
19,511
Total Support
$22,668,352
Expenditures
Research Grants
Research & Clinical Support
$19,419,295
3,249,057
Total Expenditures
$22,668,352
35
53%
20%
11%
8%
4%
2%
2%
0%
100%
to our
[donors]
To our donors with our deepest gratitude…
We wish to gratefully acknowledge all of our donors whose continued support has
allowed DRI scientists to pursue promising new research avenues, to lead with vision
into the most advanced areas of science and to keep hope alive for millions of children
and adults who dream of a cure for this devastating disease.
Our DRI family continues to grow and many new donors have joined us over this past
year. We sincerely appreciate every single gift we receive, no matter the size. We would
like to take this opportunity to recognize and thank our highest contributors, whose
unwavering dedication and unparalleled generosity has truly helped accelerate progress
toward a cure for diabetes. The individuals, families, corporations and foundations listed
on the following pages have been the backbone of this organization since our inception
almost four decades ago. Their names appear in the corresponding giving levels as of
December 31, 2009.
Again, we wish to deeply thank all of our donors the world over for your continued
support of the Diabetes Research Institute and Foundation.
Visionaries - $10,000,000+
Building and Construction Trades/AFL-CIO
J. Enloe and Eugenia J. Dodson*
Raymond and Russell Johnson*
Sylvia and Rowland Schaefer
Chairman’s Council - $5,000,000+
Polly and Baron de Hirsch Meyer*
Leon J. Simkins
Leadership Council - $1,000,000+
Michele Bowman and Joseph Underwood
Trudy and Paul Cejas
Diabetes Foundation of Florida
D.R. Donaldson Family Foundation
Randy Dorfman
The Esformes Family, Annie and
Nate Esformes
Foundation for Diabetes Research
Inserra Family Foundation
International Association of Bridge,
Structural and Ornamental and
Reinforcing Iron Workers
International Association of Heat &
Frost Insulators and Asbestos Workers
International Brotherhood of Boilermakers,
Iron Ship Builders, Blacksmiths, Forgers
& Helpers
International Brotherhood of
Electrical Workers
International Brotherhood of Teamsters
International Union of Bricklayers
& Allied Craftworkers
International Union of Elevator Constructors
International Union of Operating Engineers
International Union of Painters and
Allied Trades
The Jack Parker Foundation
Carole and Barry Kaye
Richard H. Kline*
Eleanor C. and Joseph* Kosow
Laborers’ International Union of
North America
Alfred P. LaRose*
Operative Plasterers’ & Cement Masons’
International Association of the
U.S. & Canada
Peacock Foundation, Inc.
Ricardo Puente
William and Deborah Rand
Sheet Metal Workers International
Association
Stacy Joy Goodman Memorial Foundation
Dr. Denise R. and Thomas D. Stern
United Association of Journeymen &
Apprentices of the Plumbing & Pipe Fitting
& Sprinkler Fitting Industry of the U.S.
& Canada
United Brotherhood of Carpenters &
Joiners of America
37
United Union of Roofers, Waterproofers
and Allied Workers
Jill and Cliff Viner
Governors’ Society - $500,000 +
Jeanne and Virgil Christopher*
Rose Cohen*
Tom Curtis
Kelly and Harold Doran
E.R.A.S.E. Diabetes
Joan and William J. Fishlinger
Florida Jaycees
Susan and Douglas D. Gallagher
Paola and Piero Ludovico Gandini
Richard L. Gelb Family
Las Vegas Meetings by Harrah's
Entertainment
Louise K. and Robert T. Held, Sr.*
Lola and Donald Jacobson
Blanche E. Kroloff*
Amy and Alan Meltzer
Million Dollar Hole in One
Risa and Jeff Pulver
Red Apple Group
Redfern Foundation
Valerie and Camillo Ricordi
The Family of Samantha Max Stern
Ferne and Daniel Toccin
ULLICO Management Company
Roberta and Bruce Waller
Distinguished Humanitarians $250,000+
Elizabeth M. and Robert W. Bradley*
Jane and Bill Burt*
Henry E. Caballero*
Ivette and Juan Calles
Pearl Coulter*
Diabetes Research & Wellness Foundation
Lloyd and Helen Dilworth Foundation
Florida Power & Light Employees
Jeanine Forman-Ham
Florence Frank
Paula N. Freund*
Future Leadership Foundation, Inc.
Dr. and Mrs. Phillip T. George and Family
Linda and Barry Gibb
Mary and Jay N. Goldberg
Martin Granowitz
Jill and Allen Greenwald
Fran and Mel Harris
The Barbara and Sam Herzberg Family
The Holtz Family
IBM Foundation and Employees
Louis Kaczmarek*
Isolde Kaskel*
The Martin Kleiman Family
Connie and Harvey Krueger
Tova Leidesdorf
Lions Club International
Eleanor Lowe*
Francine Lowe
Isabel and Sam* May
Micki* and Joseph Mele
Charlotte and Eugene Milgram
The Mostyn Foundation
Brenda Novak's Online Auction For Diabetes
Fred and Mabel R. Parks Foundation
Penny and Robert A. Pearlman
Phil Peterson Key West Poker Run, LLC
Cristina and Ramon Poo
The Seaver Institute
Miriam and James J. Sensale
Hazel and Marvin Shanken
Shapiro-Silverberg Foundation
Holly and David Sherr
Muriel and Sherman Simon
Philanthropic Fund
Richard H. Simons Charitable Trust
Edith and Martin B. Stein
Burton S. and Barbara F. Stern
Symonds Family
Van Pelt Foundation
Ethel J. Vilm*
Washington CLUB
Rita and Stan Weinstein
Westreich Foundation
Sally Zak*
Sonja Zuckerman
Grand Founders - $100,000+
Lisette and Norman* Ackerberg
Joseph Alexander Foundation , Inc.
Barbara and Philip Altheim
American Building Maintenance Co.
Arison Family
Aurora Foods, Inc.
Bankers Life & Casualty Co.
Autis H. Barker*
The Bastin Family
Alan Bauer*
Diane and Bernard Beber
Margaret and Raymond Berner
Buddy Blair*
Nancy and Jerry Blair
Martha and Tom Blash*
The Family of Dr. Adam H. Bloom
Boehringer Mannheim Corp.
Delores S. and William K. Brehm
Sylvia Bruce*
Marty B. Bruder
Valetta Arlene Byrn*
Carnival Cruise Lines
Cynthia D. Carr
Roberta O. and Harvey R. Chaplin
Children with Diabetes Foundation
Cohen Family Charitable Foundation
for Jake Cohen
Brian and Cheryl Coughlin
Cushman & Wakefield, Inc.
Tom Daly
Dotty and George* D’Amato
Reva Dauer*
Lucille S. Dell*
The DeMatteis Family Foundation
Jodi and Bob Dickinson
Robert E. Dooley
The Durst Organization
Cindi and Paul Elias
Cindy Epstein
The Charles Evans Foundation
Raymond Falkenstein*
Elizabeth and Max Feldberg Fund
Eric Feiler*
Fidelity National Title Insurance Company
First Quality Maintenance LTD.
Randy and Mark Fisher
Derry and Steven Fishman
Michael J. and Katherine E. Franco Foundation
Fraternal Order of Eagles
Marvin Ross Friedman
Sherrie Garfield in Memory of
Joseph Garfield*
Gibb Family Foundation
Glen Cove Police Benevolent Association
Nancy and Lawrence E. Glick
Esther and Marc S. Goodman
Jane and Jerrold F. Goodman
Alvin Grabow*
Linda and Glenn Greenberg
Maurice R. and Corinne P. Greenberg
Elizabeth A. Guon*
Elizabeth and Gary Hall, Jr.
Shirley D. Harris
Arthur H. Hertz
The Hatz Family
Kirsten and Steven Heinemann
John W. Henry
Judith and Lawrence Howard
JAD Corp. of America
Lynne and C. Shelton James
Paul Tudor Jones
The Max and Yetta Karasik Family Foundation
Henry A. Keller, Jr.
Joan Keller
Sue and Norman Kenyon
Barbara and Martin P. Klein
Priscilla & Ira Kleinberg Foundation
Sylvia Kwasha*
Ladyzinski Family Foundation
Lucrezia and Vito LaForgia
Oscar and Vivian Simkins Lasko
Barbi and Warren Lazarow
Pat and Mac Levitt
Sandra and Sidney Levy
Robert Mace
Anna Machado*
Beverly and Mel Marks
Julia and Gilbert Merrill Foundation
Miami Beach Chapter/NCCH
Miccosukee Tribe of Indians of Florida
Dottie and Julie Miller
Matthew Miller Family
Jeffrey Modell Foundation
Mutual of America
Sheila and William Natbony
The Norjana Charitable Foundation
Novo Nordisk Pharmaceuticals
Olstein Family Foundation for Brooke Goldfarb
Onesource Facility Services, Inc.
In memory of my wife, Laurie R. Parham,
Ted Parham*
Jane Parker and Francis Cosentino
Feli and Gerd Petrik
Carolyn Pflugk in Memory of Peter Pflugk
Steven Posner and Kathryn Chesler
John Reisman
Judith A. and Paul B. Reisman
The Retirement Research Foundation
Margaret H. Reynolds*
Jed Ringel
Marion A. Roletti Foundation
Sondra Rose
The Rose and Burton Kahn Family Foundation
Ruth and Albert* Rosenberg
Kelly and Charles Royal
Madelyn Rubin
Mark R. Rubin
Charles Sakele*
Leslie and Ricardo Salmon
Sandoz Research Institute
Ruth and Samuel Schwartz*
Inge and Maurice Schweizer*
Barbara F. Scott
Jacci S. and Floyd E. Seskin
Shell Key West Challenge
The Morton F. Silver Family
Freda F. Silvers*
Kathy Simkins
Barbara and Sheldon Singer
S L Green Management LLC
Louise B. Soehner*
Jana and Steven Sonberg
South Florida District Optimists International
Spear, Leeds & Kellogg
Sportsmen for Charity
The Starr Foundation
Gerald J. Steinberg*
Sandy and Paul Steinberg
Frank Strick Foundation
Marilyn and Gary Studley
Suburban League
Jack Taylor Family Foundation
Anna and Leonard Thun
Tiffany & Co.
Turner Construction Company, Anaheim, CA
Lois and Joseph Umbach
William T. Voigt*
Walgreens
Barton G. Weiss
Dorothy and Jack Weiss
James Wenck, Jr.*
Lois and Richard Werner
Helene Westreich
Dr. Jack Widrich Foundation
Susan Winberg and Kenneth Shewer
Cynthia and Philip Wolman
Ann Zorn*
Barbara and Martin E. Zweig
Founders - $50,000 +
Dr. and Mrs. Vincent J. Abbatiello
Abbott Diabetes Care
ACC Construction Corporation
Adco Electrical Corporation
Carl J. Althoff*
The Jeffrey A. Altman Foundation
and Owl Creek Asset Management
Ambassador Construction Co., Inc.
American Airlines
American Fruit & Produce Corp.
Americana Manhasset
Barbara Annis
ATCO Properties & Management, Inc.
Lillian Baker*
The Bakery, Confectionary, Tobacco Workers
and Grain Millers International Union
Victor Ballard*
Marlene and David Berg
Biogen, Inc.
Blank Family Foundation, Inc.
Belle and Albert* Blanton
Esther Blattner*
Carol Nudelman Blumberg and
Morton Blumberg
Boca Group International, Inc.
The Linda and Douglas Boyd Family
C. Allen Brice
Philip Brice
Rita and Samuel* Brodie
BrookBridge Consulting Services, Inc.
Bvlgari
C.H. Robinson Company Worldwide, Inc.
Camp NYDA Junior Division, Inc.
Mary and Stephen Carner
The Carrion Family
Carrousel
Chase Manhattan Bank
Tracy and James Ciocia
Citigroup
Beatrice Clancy
Carole and H. L. Clark
Collins Building Services, Inc.
Terry Cook*
Dr. Stephen B. Colvin* and
Mrs. Helane Brachfeld-Colvin
ConEdison Solutions, Inc.
Murray Cornblum
Coscan Waterways
In Memory of Pat Covelli
Arlyn and Stephen Cypen
Damon Biotech
Gertrude Davenport*
Kathleen and Charles Delle Donne
Delta Air Lines
Gail and Charles DelVecchio
Gillian and Elliot* Dinnerstein
Charles Domina
Gary Dubin
Maxine Dubin
Betty and Lowell Dunn
Durnan Group, Inc.
Eli Lilly & Co
CB Richard Ellis
F.J. Sciame Construction Co., Inc.
The Mary Farrell and Stuart Bloomberg Family
Chris and Kevin Fee
The Milton and Sally Feldman Foundation
Doris Felner*
Claudia M. Ferero
Firequench, Inc.
Mary Beth and Bruce Fishbein
Valerie and Marc Fishman
Shirley Fletcher
Fluor Constructors International, Inc.
Kathi and Scott Forbes
The Foundation for Transplant Research
Patricia Frankel
Edith and Sol Freedman
Jack & Pauline Freeman Foundation
Christine M. Frick*
Joel S. Friedman and Victoria Agron
Milton I. Friedman*
John Gallin & Son, Inc.
Joan Galison
Gladys and Martin Gelb
The Genatt Family
Herbert and Elaine Gimelstob
Becky and Braxton Glasgow
Gloria* and Stanley Goldman
Moises T. Grayson
Amy, Scott, Jonathan & Lexi Greenwald
Grossjung Foundation
Grubb & Ellis
Guardian Service Industries, Inc.
Edgar and Frieda Hamm Trust
Kenneth Harple
Harvard Maintenance, Inc.
Sigrid Haukland*
Health Foundation of South Florida
Hector Family Foundation
Lady Monica Heftler
Heisman Trophy Trust
Roberta and Lawrence Helfant
H. Kurtz Henley*
Gertrude Hirsch
Iacocca Foundation
IESI Corporation
Insulin-Free World Foundation
JDP Mechanical, Inc.
Johnson and Johnson Family of Companies
Kenny Johnson
Mollie Kalman*
Reuben Kaplan*
Amy Katz
Eleanor and Herbert* Katz
Helene and Stanley Kellert*
Kelly Press, Inc.
Patricia and James Kennedy
Tammy and Steven Klein
Stanley M. Kossoff
Burt Kozloff
Janie and Ron Kupferman
Kenneth A. Lattman Foundation, Inc.
Maximilian Lavine*
Lehman Brothers
Fran and Robert Leichtung
Thomas J Lipton, Inc.
Ann and James Long
Long Island Board of Realtors
Joan and Martin Maddaloni
Magnus and Petherick Family
Mainco Elevator & Electrical Corp.
Medimmune
Milrose Consultants, Inc.
Mitzi and Sol Center
Marie G. Morandi
MOSAIC
M-T-M Printing Co., Inc.
Mystic Pointe
Neiman Marcus
Neocrin Company
New York City Transit Authority
Judy and J. P. Newell, III
Newmark & Company Real Estate, Inc.
Kathryn A. Nicolosi
The Nieweg Foundation
NMAPC, Inc.
The Oringer Family Foundation
Lisa and James Pappas
Louise and Allan Pashcow
Perlmart
The Picard Family
Ruth and Nathan Plaks
Platinum Maintenance Service Corp.
Louise and Faustino Poo
Porsche
Ethel C. Posnick
The Puntillo Family
Quality Building Services Corp.
Quality Fire Protection Consultants, Inc.
Raymond C. and Diane F. Radigan
In memory of my husband John, Lillian Redlich
Maria and Eric Reeps
Gertrude Reis*
Remco Maintenance Corporation
Marie and Charles Rizzo
39
Blanca I. Rodriguez
Helen L. Rossi*
Iris and Gene Rothstein
Florence and Arnold Rubin*
Gloria and Dr. Larry Ruchman
Olga and Carlos Saladrigas
Roberta Sands
Irela and Jose Saumat
ScheinMedia
Schindler Elevator Corporation
Richard Schoninger and The Schoninger Fund
Bruce and Mary Jo Schumin
The Segel Company, Inc.
Mildred and Julius Ser
Tom Shanks
Sherwood Medical Industries
Iris and Milton Shlansky
Natasha and Thomas Silver
Lenore Toby-Simmons and Dr. Bernard J.
Simmons
The Simon Foundation
Rose Sipocz*
Sandra Smith
Alan Smurfit
Claudine Smurfit
Iolanda M. Sobol
Donald Soffer
Frosene Sonderling*
Southern Wine & Spirits of South Florida
Abbe and Eric Spar
Marilla M. Spear*
Joan Spector
Stanford Financial Group
Debbie and Lou Steiner
Structure Tone Inc.
Ted Moudis Associates, Inc.
To The Point
Together Against Diabetes
The Torch Foundation
Transel Elevator and Electric, Inc.
Triangle Services, Inc.
Turner Construction Company, New York, NY
Unity Electric Co., Inc.
Vanguard Construction &
Development Co., Inc.
VITAZEST Water - Triple A Products, LLC
Vivotech
The Reverend Ann Walling
Rina and Jerrold Weinbrom
Laura Weinsoff
Anne Weinstock*
Laurie and Lawrence Wells
Leslie Westreich
Rhoda and Donald White
Dan Whitney a.k.a. Larry the Cable Guy
Marion and Robert S. Wilson
The Paula and Tom Wilson Family
Josephine Wolf*
Wollowick Family Foundation
Zwicker Electric Co., Inc.
Benefactors - $25,000+
ABM Janitorial-Northwest
A.F. Best Securities, Inc.
A/R Environetics Group, Inc.
Abbey Foundation
Jayne and Leonard Abess/City National
Bank of Florida
Alice and Arthur Adams*
Sari and Michael Addicott
Adelhardt Construction Corporation
Arthur and Shelley Adler
Annette and Lee Aerenson
AFL-CIO Housing Investment Trust/AFL-CIO
Building Investment Trust
Ahmuty, Demers & McManus
AIG
Armando Alejandre Jr. Memorial Foundation
Carmen Alexander-Printup* and
Michael C. Alexander
Allergan Medical Optics
Amalgamated Transit Union
American Healthcorp., Inc.
American Home Products Corp.
American International Group
A-One-A Produce & Dairy
Aragon, LLC
Architectural Tile Restoration, LLC
Helen M. Aren*
Peggy and Joseph Armaly
The Artzt Family
ASM Mechanical Systems
Sallie* and David Balogh
Lydia and Paul Balzano
George W. Bauer Family Foundation
Bay Area Produce
Bear, Stearns & Co., Inc
David A. Beckerman Foundation
Marie Belanger
Suzanne and Marc Bell
Arvilla and Leo* Berger
Ruth and Philip Berman
Betagene Incorporated
Suzanne and Donald Bezahler
Jennifer and Robert C. Bills
Biscayne Greyhound Track
Blavin & Company, Inc.
Bloomberg
Ted Bodin*
Michele and Peter Bongiorno
Boston Properties, LP
The Boult Family Foundation
Bovis Lend Lease, Inc.
Bravo Brands Inc.
Bristol-Myers Squibb Company
Romero Britto
Dorothy and Michael Brumer
Buchwald Jewelers
Marilyn Cahn
Kate Callahan and Peter Benjamin
Calvin & Flavia Oak Foundation
Canyon Ranch Health Resort
Cartier, Inc.
Sophia and William J. Casey Foundation
CBRE Real Estate Services, Inc.
Lee and Sidney Charnin
Elizabeth Cheval
Deborah Chodrow
Edwin S. Chua and Lori Dolce
Cilco, Inc.
Citrix Systems
Karen B. Cohen
Mr. and Mrs. Michael Cohen
Ralph Cohen*
Vivian Cohen*
Comet Electric
Mabel B. Conklin
Gertrude and Jack* Cooper
Miller Cooper
Lorraine and Sidney Cooperman
Cathie and Robert Cornacchia
Cornblum Family
Corporate Interiors Contracting, Inc.
Couts Heating and Cooling Inc.
Cure Diabetes Now
Jane and Lawrence David
Merle M. DeLancey
DeLancey Printing
Delicious Brands, Inc.
Kim and Jordan Dickstein
Ann and Norman Didriksen
Distillery Wine and Allied Workers
Donaldson Acoustics Co., Inc.
Amy and William Donner
Debbie and John Drury
Dudley Foundation
Mildred Edelstein*
Edmar Cleaning
Lola and Gus Efthimiou
Sheila Elias
Susan and Gerard Elicks
Gail E. Ellis and Sandy J. Fox
Empire Office, Inc.
Chase Enterprises
Erectra Construction Corp.
ESS & VEE Acoustical Contractors, Inc.
Eurohypo AG
Rosa and Francis Feeney
Iris and David Feldman
Mr. and Mrs. Keith Fell
Marilyn Fellman
Fine Art and Craft Co., Ltd.
Pamela and Barry Fingerhut
Lillian Fiolic*
Fisher Brothers Management Co.
FIT USA Foundation
Florida Association of Furniture
Manufacturers
Florida District Kiwanis
Florida Mushroom, Inc.
Fred Geller Electrical, Inc.
Fried, Frank, Harris, Shriver & Jacobson
In Loving Memory of Fred Friedland
Friends United for Diabetes Research
Doree and Malcolm Fromberg
Thomas E. Frueh*
G.L. Homes of Florida Corporation
Anne Gache
Mira and Murray* Gaines
Gardiner & Theobald Inc.
Gina and Peter Gardner
Gensler
The GEO Group
Friends of Robert A. Georgine
Suzanne and Thomas* Gerard
Niety and Gary Gerson
Arnold Gertner
Bunchy Gertner
Judy and Robert Giaquinto
Susan and Arthur Gillin
Dalia and Saul Glottmann
Marion and Donald Golden
Carolyn and Marc Goldfarb
Debora and David Goldfarb
Goldman Sachs and Company
Bella and Lester* Goldstein
Lorraine Goldweber*
Jennefer and Ian Goodman
Nettie Gratkowski*
Ellen and Irving Grauer
Sylvia Gray
George Green
Danielle and Troy Gregory
James and Betty Guy
Susan and Alan Habacht
Amy and James Haber Foundation
Norma and Herbert* Hackmeyer
Patrick and Mary Hall
Joseph and Sally Handleman Foundation Trust
Daniel J. Hannon
Hanover Moving & Storage Co., Inc.
Deana and Stephen Hanson
Nicki and J. Ira Harris
The Headlands Foundation
Health Net, Inc.
Ellen and Barry Heimlich
Christopher and Joie Hein
Mr. and Mrs. Robert T. Held, Jr.
Mary K. Heller*
Marilyn and Carl Hellman
Janet and Barrett Hess
Madeline and Herbert Hillsberg
Louis Hirschfield
The Hirshleifers
HLW International LLP
Hochberg Family Foundation
Lee S. Hochwald*
The Homan Foundation
Home Savings Bank of Florida
Hotel Employees and Restaurant Employees
International Union
Household Credit Card Services
Edith and Robert Hudson
Peter Huri
ICAP Services North America LLC
Insignia/ESG, Inc.
International Association of Fire Fighters
Intracoastal Abstract Co., Inc.
J.T. Magen & Company Inc.
Myra and Allen Jacobson
JC & F Services, Inc.
The Joachim Family
Jones Lang Lasalle Americas
Max D. Josephson*
Juvenile Diabetes Research Foundation
International
K & R Industries
Kaback Enterprises, Inc.
Charlotte and Louis Kaitz
Howard Kane
Mr. and Mrs. Michael A. Karsh
Marsha and Arthur Katon
Joan and Myron Kaufman
Beth and Sy Kirshner
Klear Electrical Corp.
Merrick R. Kleeman
Harry Klein*
Sheila and Arthur Kline
Knight Electrical Services, Corporation
Gary Koenig, in Memory of Walter D. Koenig
Helene and Marc Kovens
Debra and Jerry Kramer
Alvia Kreher*
Bertha Kubler
L & K Partners, Inc.
Nancy and Richard Ladd
LandAmerica
Laurie and William* Landau
Brian and Jill Landow
Lane Office Furniture, Inc.
Laro Service Systems, Inc.
Lazard Freres & Co., LLC
Lehr Construction Corp.
Carole and Marvin Leichtung
Jan and Arthur Leichtung
Ellen and Joseph Leondis
Joan and John Leondis
Evelyn C. Levine*
Meryl R. Lieberman
Lodi Markets, LLC
JoAnn B. Long
Dr. and Mrs. John Lovecchio
Lowenstein Sandler PC
The Luebs Family
M. Robert Goldman & Company
Alice Mace
Macklowe Management Co. Inc.
Margot Madans
Mailboxes, Etc.
Jack N. Mandel
Diane and Paul Manning
Marino Gerazounis & Jaffe Associates, Inc.
Lisa and Richard Mattaway
Linda and Bill McDonald, Jr.
MC Energy Inc.
Scott McDonald and Tiffany Schauer
McGann Family
Lois and Marvin L. Meitus
Mercedes Benz of Palm Beach
Joseph Messana
Metropolitan Steel Industries, Inc.
Linda and Thomas Meyer
The Milch Family Foundation
Dawn Mintz Memorial Fund
Marge K. and Dr. Daniel H. Mintz
Martha Mishcon
Monster Worldwide, Inc.
Monterey Fund, Inc.
Edward Moss
Stephen and Sandy Muss
H. Herbert Myers Memorial Foundation
National Association of Letter Carriers
National Distributing Company
National Music Publishers Association, Inc.
Dr. Robin Nemery and Barry Hauser
Eleanor & Roy Nester Family Foundation
Sheldon Neuman*
New York Community Bank Foundation
New York Elevator Company, Inc.
Ann and Jack Norman
Northland Cranberries, Inc.
Novocell, Inc.
Sandra Nowicki
Otis Elevator
Natalie and Michael* Pelavin
Rosalie and Stephen Pandol
Parents for the Cure
Perry Ellis International Inc.
David J. Peterson
Ruth Pfeffer
Plaza Construction Corporation
Simon Portnoy
Victor Posner*
Hildine and Jerry Potashnick
Premier Restoration Technologies, LTD.
The Produce Connection
Prudential Financial
Norma and Luis Quintero
Rafa Machinery and Engineering
Real Estate Media
Rosalind and Daniel Richter
Myrna and Norman Ricken
Marsha and Barry Ringelheim
Heather and Charles A. Ritter
Robert Stigwood Organization
Joan and Gerald Robins
Deborah and Scott Robins
Loree Rodkin
Helen and James Rosburg
Harry & Bessye Rosenberg Charitable Trust
Seymour Rosenberg
Blanche I. Rosenblatt
Mr. and Mrs. Maurice A. Ross
Maritere and Jorge Rosso
The Rothstein Family
Ruth Rubenstein*
Adrienne R. and Arnold J. Rubin
Alice and Seymour Rubin *
S.I.U. of North America
Sager Development/Subway
Saks Fifth Avenue
Salomon Smith Barney
Faryl and Jonathan Sandler
Gerald P. Schein
Jill Schildkraut-Katz
Sue Schonfeld
Patricia and Leonard Schupak
Donna and Marvin Schwartz
Beatrice & Samuel A. Seaver Foundation
Michele and Norman* Seiden
Samantha Shanken and Michael Baker
Barbara and Norman Shapiro
Sanjiv Sharma and Nadine Allen
Louis K. Sher
Dana and Andrew Shore
Show Management Concession Inc.
Sheila and Joseph Shulevitz
The Silva Family, in Memory of Barbara Katz
Casey and Matt Singer
Samuel Singer*
Dolly and Mitchell Sirgany
Skadden, Arps, Slate, Meagher & Flom LLP
Jay Skyler and Mercedes Bach
Bernadette and Owen Smith
Linda and Frank Smith
Standard Drywall, Inc.
Starvin Marvin Jewelry Inc.
Steelcase Inc.
Rhoda Stern
Strauss Paper Company, Inc.
Stuart Dean Co., Inc.
Sugarman Family Partners in Memory
of Fred Krutel*
Cindy and Michael Sweeney
Team FootWorks
Temco Service Industries, Inc.
Tennessee Valley Authority
Rick, Margarita and Steven Tonkinson
Top Tomato Company
Tropical Shipping
U.S. Trust Bank of America Private
Wealth Management
Union Bank
The Union Central Life Insurance Company
United Food & Commercial Workers
International Union
United States Sugar Corp.
Vornado Office Management
Vornado Realty
Judy and Bruce Waldman
Thomas J. and Holly C. Weger
Carole and Marcus Weinstein
Susan Blash Weiss and Gary Weiss
Wells Fargo Foothill
The Wilfork Family
Winn-Dixie Stores, Inc.
Marcia and Leon* Winograd
Sheila Wohl
Laurence G. Wolf
Marsha and Fred Wolinsky
41
Yates Restoration Group Ltd.
In Memory of Lucian Zadrozny
Deborah and Jeffrey Zane
Althea Brandner Zansler
Donna and George Zoley
Mary Zuk*
*deceased
heritage
[society]
Nancy Barr Bisco
E. Diane Beber
Thomas and Martha Blash*
Michele Bowman and
Joseph Underwood
Annemarie and Lester Brockman
Marty B. Bruder
Jane D. Burt*
Henry Caballero*
Ivette and Juan Elias Calles
Jeanette Carmel*
Tom Curtis
Aldo Del Re*
Cindi and Paul Elias
Eric Feiler*
Carole D. Franklin
Sherrie and Joseph* Garfield
Stanley J. Garfinkel
Dr. and Mrs. Phillip T. George
Elizabeth A. Guon*
J. Jean Hacker*
Kenneth G. Harple
Shirley Harris
Frances Harrow
Larry Hassenbein
Don and Diane Holmes
Shirley M. Hotto
Jill and Thomas Karlya
Carole and Barry Kaye
Dr. Norman and Sue Kenyon
Richard H. Kline*
Eleanor Kosow
Rose B. Kramer
Rebecca Krawitz*
Sara Kupchik*
Marc D. Levine*
Margot Madans
Muriel B. Mele*
Jill and Gary Miller
Howard C. Neumann
Kim and Beverly Newlin
Eleanor J. and Laurence
S. Newman*
David Papier
In memory of Laurie R. Parham
Ruth Plaks
Betty Pinto*
Barbara C. Popp
Hildine and Jerome Potashnick
Lori Chadick Randell
James and Dr. Wendy Rapaport
Lillian Redlich
Gertrude Reis*
Margaret H. Reynolds*
Jo-Ann Rifkind
Susan and Neil D. Rosenberg
Beatrice and William Sahm
Charles Sakele*
Arline B. Schaeffer
Kimberly Schlom
Maurice and Inge Schweizer*
Seskin Family Foundation
Barbara and Sheldon Singer
Elda Bello Spano
Emilia M. Stark
Gale Goldstein Tucker
Ilene and David Vinikoor
Simon H. and Sandra F. Waugaman
Esther Weingarden*
Laura Weinsoff
Lori and Lary Weintraub
Susan Blash Weiss and Gary Weiss
Julius Werbner*
Adele Wilson*
Sally D. Zak*
Morris Zell
Don Zipern
Ann Zorn*
*deceased
national
[board of directors]
Chairman
Thomas D. Stern
Chairman Emeritus
Marc S. Goodman
Vice Chairmen
William J. Rand, M.D.
Charles Rizzo
President and CEO
Robert A. Pearlman
Treasurer
Harold G. Doran, Jr.
Secretary
Barry C. Hauser
Directors
Mark H. Ayers
Bernard Beber, M.D.
Diane Beber
Marlene Berg
Juan Elias Calles
Brian Coughlin
Nathan J. Esformes
William J. Fishlinger
Jeanine Forman-Ham
Douglas Gallagher
Piero Gandini
Lawrence E. Glick
Jay N. Goldberg
Esther Goodman
Jerrold Goodman
Arthur Hertz
Lawrence Howard, M.D.
Bonnie Inserra
Glenn Kleiman
Martin P. Klein
43
Eleanor Kosow
Harvey M. Krueger
Sandra Levy
Allan L. Pashcow
Ramon Poo
Risa Pulver
Michelle Robinson
Ricardo Salmon
Kenneth A. Shewer
Kathy Simkins
Sheldon L. Singer
Steven Sonberg
Jill Viner
Michael Wallock
Sonja Zuckerman
honorary
&
regional
[boards]
Florida Board
of Directors
Northeast
Board of Directors
Long Island Board
of Directors
Honorary Board
of Directors
Chairman
Chairman
Chairman
William J. Rand, M.D.*
Ricardo Salmon*
Allan L. Pashcow*
Directors
Vice Chairman for Events
and Public Relations
Executive Committee
Lynne and Martin Baron
Barbara and H. Tod Berman
Paul Cejas
John Drury
Annie Esformes
Linda and Jay Finkelstein
Bernard Fogel, M.D.
Edward T. Foote, II
Samuel J. Fox
Lisa and Mark M.
Freedman
C. Thomas Gallagher
Gladys and Martin Gelb
Linda and Barry Gibb
Yvonne Gibb
Dwina and Robin Gibb
Bella Goldstein
Jane Goodman
Senator Bob Graham
Mary Lou and
Robert T. Held, Jr.
Fana and Abel Holtz
Lola and Donald
Jacobson
Stanley M. Kossoff
Robert Leichtung
Sidney Levy
Charlotte and
Eugene Milgram
Martha Mishcon
Marge Kleiman Mintz
Stephen Muss
Judy and J.P. Newell, III
Edward James Olmos
Blanche Rosenblatt
Florence and Arnold Rubin
Rowland Schaefer
Donna Shalala
Serena and
Leon J. Simkins
Oscar Sotolongo
Ferne and Daniel Toccin
Dottie and Jack S. Weiss
Kelley Kosow Werner
Lenny Wolfe
Sari Addicott
Bernard Beber, M.D.*
Diane Beber*
Juan Elias Calles*
Bruce Fishbein
Jerrold Goodman*
Rene W. Guim
Barry Hauser*
Barbara Herzberg
Javier Holtz
Norman Kenyon, M.D.
Vito La Forgia
Sandra Levy*
Micki Mele
Carol Nudelman, Ph.D.
Ramon Poo*
Cristina Poo
Deborah Rand
Michelle Robinson*
Madelyn Rubin
Rosa Schechter
James Sensale
Jacci Seskin
Lou Steiner
Don Strock
Gary Studley
Stephen Wagman
Rita Weinstein
Linda Widrich Weitz
Sonja Zuckerman*
* also member of the
National Board of
Directors
Risa Pulver*
Directors
Barbara Annis
Diane L. Cohen
Peter L. DiCapua
Kim Dickstein
Joel S. Friedman
Richard M. Fuscone
Jay N. Goldberg*
Marc S. Goldfarb
Esther Goodman*
Marc S. Goodman*
Alan Kava
Meryl Lieberman
Samantha Shanken
David Sherr
Kenneth A. Shewer*
Steven Silva
Thomas P. Silver
Thomas D. Stern*
Geoffrey L. Symonds
William J. Fishlinger*
Barbara Hatz
John Luebs
Hon. C. Raymond
Radigan
Charles Rizzo*
Directors
Barry Ballen
Michele Bongiorno
Peter Bongiorno
Debra Carrion
John Carrion
Douglas R. Donaldson
Joan Fishlinger
Iris Feldman
Addy Fritzhand
Jon Hatz
Brian Landow
Jill Landow
Frances Luebs
Louise Pashcow
Marie Rizzo
Miriam Shiff
Bruce Waller
Roberta Waller
Delia Whitton
drif
[staff ]
National Office
Mary Revie
Northeast Region
Administrative Assistant
Robert A. Pearlman
Rick Lepkowski
President and
Chief Executive Officer
Helen Segel
Deborah L. Chodrow
Mylinda Auguste
Chief Operating Officer
Data Entry Clerk
Jeffrey Young
Marisol McKay
Chief Financial Officer
Data Entry Clerk
Tom Karlya
Lori Hester
Vice President
Receptionist
Jill Shapiro Miller
Eddy Garcia
Vice President of Gift Planning
Courier
Lauren Schreier
Director of Marketing &
Communications
Jill Ann Pall
Special Events Director
Jill Salter
Development Coordinator
Long Island Region
Anthony E. Childs
Long Island Regional Director
Lily Scarlett
Lori Weintraub, APR
Vice President of Marketing
& Communications
Northeast Regional Director
Executive Assistant
Director of Special Events
Florida Region
Melinda Ginsberg
Sheryl Sulkin
Special Events Coordinator
Director of Special Events
Brian Huether
Associate Director of Special Events
Margaret Cassani
Administrative Assistant/
Receptionist
Barbara Singer
Director of Special Projects
Stacy Zolotin
Gift Planning Manager
Nicole Otto
Assistant Director of Special Events
Aurora Nunez
Administrative Assistant
Natasha Norris
Communications Coordinator
Karen Paraboo
Administration and Database Coordinator
Laurie Cummings
Communications Assistant
Oneida Osuna
Accounting Assistant
45
.
Diabetes Research
Institute Foundation
Long Island
410 Jericho Turnpike
Suite 201
Jericho, NY 11753
Telephone 516.822.1700
Fax 516.822.3570
Northeast
381 Park Avenue South
Suite 1118
New York, NY 10016
Fax 212.888.2219
Designed by Franz Franc Design Group
National Office
Florida Region
200 South Park Road
Suite 100
Hollywood, FL 33021
Toll-free 1.800.321.3437
Fax 954.964.7036

leading with vision - Diabetes Research Institute

Transcription

Similar documents

Education

ARC factsheet Special Research Initiative for Type 1 Juvenile

NIDDK Medical Student Research Program in Diabetes and Obesity

Tim McGraw has a challenge for you.

Living with diabetes

Diabetes, Type 1

Summary of University of Surrey Academic F2 projects 2012-15

Read full article - West Feliciana Parish Hospital

Diabetes, Incorporated

Sponsor a Child and Save a Life - International Diabetes Federation